BioSante Pharmaceuticals Inc. (BPAX) is in talks to partner on its sex gel to raise female libido or sell the company, according to Chief Executive Officer Stephen Simes. The shares rose to their highest value since 2008. Scientists have tried to chemically treat female sexual dysfunction since Pfizer Inc. (PFE)’s Viagra, with $1.9 billion in 2010 sales, was introduced 13 years ago for erectile dysfunction in men. After failed attempts by Pfizer, Boehringer Ingelheim GmbH and Procter & Gamble Co. (PG), BioSante, based in Lincolnshire, Illinois, is next in line seeking to capitalize on the idea.
